Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06807424 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
A Phase 3 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT06807424: Recruiting Phase 3 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
NCT06807424 is a Phase 3 study of Arthritis, Psoriatic that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 750 participants, above the 530-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (42% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06807424, a Phase 3 study of Arthritis, Psoriatic, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Primary Outcome
The ACR 20 responders are participants with an improvement of greater than or equal to (\>=) 20 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale (VAS), patient's global assessment of disease activity \[arthritis, VAS\] scale, Physician's global assessment of disease activity VAS scale, Health Assessment Questionnaire and C-reactive protein).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Icotrokinra
Study Locations (20)
Florida
- Clinical Research of West Florida - Clearwater
- Omega Research Consultants - DeBary
- Suncoast Clinical Research - New Port Richey
- Integral Rheumatology And Immunology Specialists - Plantation
- Clinical Research of West Florida - Tampa
Texas
- Arthritis and Rheumatology Research Institute - Allen
- UT Southwestern - Dallas
- Naiara Alvarez MD Integrative Rheumatology of South TX - Harlingen
- AARA Clinical Research Lone Star Arthritis and Rheumatology - Irving
Arizona
- AARA Clinical Research - Glendale
- AARA Clinical Research - Mesa
Arkansas
- Arthritis and Rheumatism Associates ARA Jonesboro - Jonesboro
Illinois
- Clinic of Robert Hozman - Skokie
Maryland
- Klein And Associates M D P A - Hagerstown
Massachusetts
- DM Clinical Research - Brookline
Minnesota
- St Paul Rheumatology PA - Eagan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2025-01-09 |
| Est. Completion | 2028-10-18 |
| Phase | Phase 3 |
What NCT06807424 shows while recruiting
NCT06807424 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 530-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06807424 names 20 study sites across 12 states, led by Florida, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT06807424 about?
NCT06807424 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis". The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
What is the current status of trial NCT06807424?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2025-01-09. Estimated completion is 2028-10-18.
What conditions does trial NCT06807424 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT06807424?
The interventions under investigation include: Placebo (DRUG), Icotrokinra (DRUG).
Who is sponsoring clinical trial NCT06807424?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06807424 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06807424's enrollment target sits among peer trials
750 4th of 16 higher than 13 of 16 other Arthritis, Psoriatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Psoriatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI